You might also be interested in:

InnoGames boosts mobile revenues by 37 percent in 2018 / Online game developer and publisher reports double-digit percentage revenue growth in its 12th year on the market

Hamburg (ots) - InnoGames, Germany's leading developer and publisher of mobile and online games, today published ...

ForaCare Suisse AG forms service-oriented partnership with B. Braun (PHOTO)

St. Gallen (ots) - - Partnership to introduce innovative health management technologies. - Initial product offering ...

German Gin Brand 'GINSTR' Expands to Asia

HONG KONG (ots) - - Cross-reference: Picture is available - Over the ...

13.07.2006 – 15:00

Daiichi Sankyo Europe GmbH

Two Traditions. One Vision.

Merger DAIICHI SANKYO EUROPE / Two Traditions. One Vision.
  • Photo Info
  • Download

    Frankfurt (ots)

    On 1 July 2006 the next step in the global integration of SANKYO COMPANY, LIMITED and DAIICHI Pharmaceutical Co., Ltd. was achieved in Europe. The current SANKYO subsidiary, SANKYO PHARMA GmbH has been renamed as DAIICHI SANKYO EUROPE GmbH.

    "Two Traditions. One Vision." The claim symbolises the merger process as well as the future of the new company," says Mr. Takashi Shoda, president and CEO of DAIICHI SANKYO COMPANY, LIMITED. "DAIICHI and SANKYO, two leading Japanese pharmaceutical companies that both have a strong tradition in pharmaceutical research and development, are combining their strengths to become a Global Pharma Innovator. The formation of DAIICHI SANKYO COMPANY, LIMITED in Japan as the joint holding company on 28 September 2005 marked the beginning of a worldwide merger process. The European part of the merger - based on the know-how and tradition of the two pharmaceutical companies - is the next important step on our way to a joint future," adds Shoda. The global integration process will be finalised by 31 March 2007.

    The first objective of the worldwide integration is to satisfy the unmet medical needs of patients and health care professionals. With a turnover of 6.8 billion euros in the fiscal year 2005 and an operating income of 1.1 billion euros, DAIICHI SANKYO has become one of the top three pharmaceutical companies in Japan and one of the top 20 pharmaceutical companies worldwide. The new company has 18,400 employees, out of which 1,700 work in Europe.

    There were two major reasons for the merger of SANKYO and DAIICHI in 2005:     Strengthening research and development in core indication areas such as cardiovascular disease, diabetes, metabolic disease, bone/joint disease, infectious disease, cancer, immunological / allergic disease Global expansion of business activities

    SANKYO and DAIICHI both have a long record of producing successful development compounds. SANKYO is the inventor of statins, which revolutionised the treatment of hyperlipidemia. The company also invented glitazone, the first class of antidiabetic medication to also have cardiovascular prevention effects. SANKYO also successfully launched its AII antagonist Olmesartan in 2002 (BENICAR(r) in US / OLMETEC(R) in Europe). It is the seventh AII antagonist launch, but global sales will already excess 740 million euros this year.

    The DAIICHI research and development (R&D) activities were focused on antibiotics, bringing world class quinolones like ofloxacin and levofloxacin to the market. With the launch of Camptosar (irinotecan HCL injection) DAIICHI has successfully entered the highly challenging and competitive oncology area.

    With an annual R&D budget of 1.2 billion euros, a new Japanese R&D powerhouse has been born for the development of a variety of "best in class" and "first in class" candidates which are currently in the DAIICHI SANKYO pipeline.

    The second objective of the merger is the further global expansion of the business. SANKYO, with a turnover of 4.3 billion euros in 2005, is already represented in the US and European markets. DAIICHI, with a turnover of 2.5 billion euros in 2005 is also focusing on the global market. Accordingly, newly established DAIICHI SANKYO Co., Ltd. has the strong intention of enhancing its business development in the global market.

    Since DAIICHI SANKYO Co., Ltd. expects the launch of some "best in class" products like Prasugrel (CS-747), an oral antiplatelet product with a superior product profile compared to previous ADP inhibitors, and Rivoglitazone (CS-011), a "Best in Class" glitazone for diabetes treatment in the next couple of years. The merger is also laying the foundation for further substantial global business expansion as well as for growth in the Japanese home market.

For further information visit

CONTACT Olaf Lamberz Corporate Communication Phone +49(0)89/78 08-442

Original content of: Daiichi Sankyo Europe GmbH, transmitted by news aktuell

All Releases
Subscribe to Daiichi Sankyo Europe GmbH
  • Printable version
  • PDF version

Topics in this relase